These findings highlight the potential of phosphoglycerate dehydrogenase as a prognostic biomarker in high-grade serous ovarian cancer and suggest its involvement in metabolic reprogramming and progression. The gene discussed is PHGDH; the disease is ovarian serous adenocarcinoma.